Treatment response to #Bulevirtide is linked to amelioration of #PortalHypertension in patients with chronic #HepatitisD

JHEP Reports
www.jhep-reports.eu/article/S258...

VIROMARKERS aims for revolution in care of people with persistent viral infections The new project is advancing biomarkers that would improve the care of people living with HIV and hepatitis D, plus stem cell transplant patients at risk of cytomegalovirus (CMV).

🌍 On #WorldHepatitisDay, discover how our @viromarkers.bsky.social project is advancing markers to predict which patients will respond best to new #HepatitisD drug #bulevirtide.
👉 europa.eu/!FfGjJN
#hepatitis #IHITransformingHealth #HorizonEU

Neglect of #HDV #HepatitisDelta in #clinicaltrials described in a poster - especially important as #bulevirtide arrives on the scene, but access and insights limited by inequity and data gaps. This work led by @mariondelphin.bsky.social

Neglect of #HDV #HepatitisDelta in #clinicaltrials described in a poster - especially important as #bulevirtide arrives on the scene, but access and insights are limited by inequity and data gaps.
This work led by @mariondelphin.bsky.social

The $GILD statement mentions there were no new concerns raised by @US_FDA regarding the safety and efficacy of #bulevirtide which already received conditional marketing authorization by @EMA_News in July 2020 under the brand name #Hepcludex

The first approval for a drug to treat #HDV in the US will have to wait. Apparently @US_FDA cited concerns over manufacturing and delivery of #Bulevirtide in its Complete Response Letter to $GILD...

@EASLedu @EASLedu @HeinerWedemeyer #bulevirtide (BLV) @ 2mg sc QD x 48 wks leads to 45% response (undect. RNA or 2 log drop with nl ALT). LSM ⬇️. ⬆️bile salts due to NTCP blocade. No SAEs but slightly more itching. Planned for 144 wks. @US_FDA currently vetting. #ILC2022